Mechanistic Insights on Viral Factors Involved in Asymptomatic COVID-19 Pathogenesis

Satinder Kaur, Renu Bala, Prakash Chandra Mishra, Vineeta Singh, Rachna Hora
{"title":"Mechanistic Insights on Viral Factors Involved in Asymptomatic COVID-19 Pathogenesis","authors":"Satinder Kaur, Renu Bala, Prakash Chandra Mishra, Vineeta Singh, Rachna Hora","doi":"10.2174/2666796704666230913105109","DOIUrl":null,"url":null,"abstract":"Abstract: SARS-CoV-2 infection may cause asymptomatic, pre-symptomatic or symptomatic COVID-19 disease. While symptomatic infections are at the centre stage for disease diagnosis and treatment, asymptomatic and pre-symptomatic cases heighten the challenge of transmission tracking ultimately leading to failure of control interventions. Asymptomatic cases appear due to a variety of host and viral factors and contribute substantially to the total number of infections. Through this article, we have tried to assemble existing information about the role of viral factors and mechanisms involved in the development of asymptomatic COVID-19. The significance of ‘PLpro’- a protease of Nidovirales order that removes ubiquitin and ISG15 from host proteins to regulate immune responses against the virus and hence disease presentation has been highlighted. PL-pro dampens inflammatory and antiviral responses, leading to asymptomatic infection. 11083G>T-(L37F) mutation in ‘Nsp6’ of SARS-CoV-2 also diminishes the innate immune response leading to asymptomatic infections. It is, therefore, pertinent to understand the role of proteins like PLpro and Nsp6 in SARS-CoV-2 biology for the development of transmission control measures against COVID-19. This review focuses on viral molecular mechanisms that alter disease severity and highlights compounds that work against such regulatory SARS-CoV-2 proteins.","PeriodicalId":10815,"journal":{"name":"Coronaviruses","volume":"26 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Coronaviruses","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/2666796704666230913105109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: SARS-CoV-2 infection may cause asymptomatic, pre-symptomatic or symptomatic COVID-19 disease. While symptomatic infections are at the centre stage for disease diagnosis and treatment, asymptomatic and pre-symptomatic cases heighten the challenge of transmission tracking ultimately leading to failure of control interventions. Asymptomatic cases appear due to a variety of host and viral factors and contribute substantially to the total number of infections. Through this article, we have tried to assemble existing information about the role of viral factors and mechanisms involved in the development of asymptomatic COVID-19. The significance of ‘PLpro’- a protease of Nidovirales order that removes ubiquitin and ISG15 from host proteins to regulate immune responses against the virus and hence disease presentation has been highlighted. PL-pro dampens inflammatory and antiviral responses, leading to asymptomatic infection. 11083G>T-(L37F) mutation in ‘Nsp6’ of SARS-CoV-2 also diminishes the innate immune response leading to asymptomatic infections. It is, therefore, pertinent to understand the role of proteins like PLpro and Nsp6 in SARS-CoV-2 biology for the development of transmission control measures against COVID-19. This review focuses on viral molecular mechanisms that alter disease severity and highlights compounds that work against such regulatory SARS-CoV-2 proteins.
新型冠状病毒无症状发病机制研究
摘要SARS-CoV-2感染可导致无症状、症状前或症状性COVID-19疾病。虽然有症状感染处于疾病诊断和治疗的中心阶段,但无症状和症状前病例加剧了传播追踪的挑战,最终导致控制干预措施失败。无症状病例的出现是由多种宿主和病毒因素引起的,并且在感染总数中占很大比例。通过本文,我们试图收集有关病毒因子在无症状COVID-19发展中的作用和机制的现有信息。“PLpro”是一种尼多病毒目蛋白酶,它可以从宿主蛋白中去除泛素和ISG15,从而调节针对病毒的免疫反应,从而调节疾病表现。PL-pro抑制炎症和抗病毒反应,导致无症状感染。SARS-CoV-2 ' Nsp6 '的11083G>T-(L37F)突变也会降低先天免疫反应,导致无症状感染。因此,了解PLpro和Nsp6等蛋白在SARS-CoV-2生物学中的作用,对于制定针对COVID-19的传播控制措施具有重要意义。这篇综述的重点是改变疾病严重程度的病毒分子机制,并重点介绍了对抗这种调节性SARS-CoV-2蛋白的化合物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信